Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Mark Hurwitz MD
To assess whether the addition of androgen suppression therapy (AST) and docetaxel to adjuvant radiation therapy (ART) improves freedom from progression (FFP) as defined as PSA < 0.4 ng/ml, and no clinical failure (local-regional, or distant failure) at 3 years.
Data for this trial is being collected via the NRG/RTOG Data Center.
Pathologically proven diagnosis of adenocarcinoma of the prostate meeting one of the following combinations:
Gleason score > = 7 at the time of prostatectomy and PSA nadir > 0.2ng/ml; Gleason score > = 8 at the time of prostatectomy and T classification > = T3a.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.